Acoustic	O
evaluation	B:C0220825
of	O
pirfenidone	O
on	O
patients	O
with	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
.	O

Acoustic	O
evaluation	O
of	O
pirfenidone	B:C0298067
on	O
patients	O
with	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
.	O

Acoustic	O
evaluation	O
of	O
pirfenidone	O
on	O
patients	O
with	O
combined	B:C3872815
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
.	O

The	O
combined	B:C3872815
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
(	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
)	O
overall	O
has	O
a	O
poor	O
prognosis	I:C0278252
with	O
a	O
5	O
-	O
year	O
survival	O
of	O
35	O
-	O
80	O
%	O
.	O

The	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
(	O
combined	B:C3872815
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
)	O
overall	O
has	O
a	O
poor	O
prognosis	I:C0278252
with	O
a	O
5	O
-	O
year	O
survival	O
of	O
35	O
-	O
80	O
%	O
.	O

The	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
(	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
)	O
overall	O
has	O
a	O
poor	B:C0278252
prognosis	I:C0278252
with	O
a	O
5	O
-	O
year	O
survival	O
of	O
35	O
-	O
80	O
%	O
.	O

Consequently	O
,	O
to	O
evaluate	O
possible	O
positive	B:C1446409
effects	O
on	O
patients	O
of	O
novel	O
agents	O
as	O
pirfenidone	O
is	O
relevant	O
.	O

Consequently	O
,	O
to	O
evaluate	O
possible	O
positive	O
effects	O
on	O
patients	O
of	O
novel	O
agents	O
as	O
pirfenidone	B:C0298067
is	O
relevant	O
.	O

However	O
,	O
the	O
efficacy	O
of	O
pirfenidone	B:C0298067
in	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
is	O
still	O
not	O
well	O
-	O
known	O
.	O

However	O
,	O
the	O
efficacy	O
of	O
pirfenidone	O
in	O
combined	B:C3872815
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
is	O
still	O
not	O
well	O
-	O
known	O
.	O

In	O
this	O
study	O
we	O
propose	O
an	O
alternative	O
to	O
evaluate	B:C0220825
the	O
effects	O
of	O
pirfenidone	O
treatment	O
on	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
via	O
acoustic	O
information	O
.	O

In	O
this	O
study	O
we	O
propose	O
an	O
alternative	O
to	O
evaluate	O
the	O
effects	O
of	O
pirfenidone	B:C0298067
treatment	O
on	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
via	O
acoustic	O
information	O
.	O

In	O
this	O
study	O
we	O
propose	O
an	O
alternative	O
to	O
evaluate	O
the	O
effects	O
of	O
pirfenidone	O
treatment	B:C0087111
on	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
via	O
acoustic	O
information	O
.	O

In	O
this	O
study	O
we	O
propose	O
an	O
alternative	O
to	O
evaluate	O
the	O
effects	O
of	O
pirfenidone	O
treatment	O
on	O
combined	B:C3872815
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
via	O
acoustic	O
information	O
.	O

Quantitative	O
analysis	O
of	O
discontinuous	O
adventitious	B:C0425542
lung	I:C0425542
sounds	I:C0425542
(	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
)	O
,	O
known	O
as	O
crackles	O
,	O
has	O
been	O
promising	O
to	O
detect	O
and	O
characterize	O
diverse	O
pulmonary	O
pathologies	I:C0748168
.	O

Quantitative	O
analysis	O
of	O
discontinuous	O
adventitious	O
lung	I:C0425542
sounds	I:C0425542
(	O
discontinuous	B:C0425542
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
)	O
,	O
known	O
as	O
crackles	O
,	O
has	O
been	O
promising	O
to	O
detect	O
and	O
characterize	O
diverse	O
pulmonary	O
pathologies	I:C0748168
.	O

Quantitative	O
analysis	O
of	O
discontinuous	O
adventitious	O
lung	I:C0425542
sounds	I:C0425542
(	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
)	O
,	O
known	O
as	O
crackles	B:C0034642
,	O
has	O
been	O
promising	O
to	O
detect	O
and	O
characterize	O
diverse	O
pulmonary	O
pathologies	I:C0748168
.	O

Quantitative	O
analysis	O
of	O
discontinuous	O
adventitious	O
lung	I:C0425542
sounds	I:C0425542
(	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
)	O
,	O
known	O
as	O
crackles	O
,	O
has	O
been	O
promising	O
to	O
detect	B:C0442726
and	O
characterize	O
diverse	O
pulmonary	O
pathologies	I:C0748168
.	O

Quantitative	O
analysis	O
of	O
discontinuous	O
adventitious	O
lung	I:C0425542
sounds	I:C0425542
(	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
)	O
,	O
known	O
as	O
crackles	O
,	O
has	O
been	O
promising	O
to	O
detect	O
and	O
characterize	O
diverse	O
pulmonary	B:C0748168
pathologies	I:C0748168
.	O

The	O
present	O
study	O
combines	O
independent	O
components	O
(	O
ICs	O
)	O
analysis	B:C1710191
of	O
LS	O
and	O
the	O
automated	O
selection	O
of	O
ICs	O
associated	O
with	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
.	O

The	O
present	O
study	O
combines	O
independent	O
components	O
(	O
ICs	O
)	O
analysis	O
of	O
LS	B:C0035234
and	O
the	O
automated	O
selection	O
of	O
ICs	O
associated	O
with	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
.	O

The	O
present	O
study	O
combines	O
independent	O
components	O
(	O
ICs	O
)	O
analysis	O
of	O
LS	O
and	O
the	O
automated	O
selection	O
of	O
ICs	O
associated	O
with	O
discontinuous	B:C0425542
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
.	O

ICs	O
's	O
features	O
as	O
fractal	O
dimension	O
,	O
entropy	O
and	O
sparsity	O
produce	O
several	O
clusters	B:C0009085
by	O
kmeans	O
.	O

ICs	O
's	O
features	O
as	O
fractal	O
dimension	O
,	O
entropy	O
and	O
sparsity	O
produce	O
several	O
clusters	O
by	O
kmeans	B:C0002045
.	O

Those	O
clusters	B:C0009085
containing	O
ICs	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
are	O
exclusively	O
considered	O
to	O
finally	O
estimate	O
the	O
number	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
per	O
ICs	O
by	O
a	O
time	O
-	O
variant	O
AR	O
modeling	O
.	O

Those	O
clusters	O
containing	O
ICs	O
of	O
discontinuous	B:C0425542
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
are	O
exclusively	O
considered	O
to	O
finally	O
estimate	O
the	O
number	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
per	O
ICs	O
by	O
a	O
time	O
-	O
variant	O
AR	O
modeling	O
.	O

Those	O
clusters	O
containing	O
ICs	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
are	O
exclusively	O
considered	O
to	O
finally	O
estimate	O
the	O
number	O
of	O
discontinuous	B:C0425542
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
per	O
ICs	O
by	O
a	O
time	O
-	O
variant	O
AR	O
modeling	O
.	O

For	O
the	O
evaluation	B:C0220825
of	O
the	O
effects	O
of	O
pirfenidone	O
,	O
the	O
2D	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
-	O
ICs	O
spatial	O
distribution	I:C0037775
in	O
conjunction	O
with	O
the	O
estimated	O
number	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
events	O
are	O
shown	O
.	O

For	O
the	O
evaluation	O
of	O
the	O
effects	O
of	O
pirfenidone	B:C0298067
,	O
the	O
2D	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
-	O
ICs	O
spatial	O
distribution	I:C0037775
in	O
conjunction	O
with	O
the	O
estimated	O
number	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
events	O
are	O
shown	O
.	O

For	O
the	O
evaluation	O
of	O
the	O
effects	O
of	O
pirfenidone	O
,	O
the	O
2D	O
discontinuous	B:C0425542
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
-	O
ICs	O
spatial	O
distribution	I:C0037775
in	O
conjunction	O
with	O
the	O
estimated	O
number	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
events	O
are	O
shown	O
.	O

For	O
the	O
evaluation	O
of	O
the	O
effects	O
of	O
pirfenidone	O
,	O
the	O
2D	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
-	O
ICs	O
spatial	B:C0037775
distribution	I:C0037775
in	O
conjunction	O
with	O
the	O
estimated	O
number	O
of	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
events	O
are	O
shown	O
.	O

For	O
the	O
evaluation	O
of	O
the	O
effects	O
of	O
pirfenidone	O
,	O
the	O
2D	O
discontinuous	O
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
-	O
ICs	O
spatial	O
distribution	I:C0037775
in	O
conjunction	O
with	O
the	O
estimated	O
number	O
of	O
discontinuous	B:C0425542
adventitious	I:C0425542
lung	I:C0425542
sounds	I:C0425542
events	O
are	O
shown	O
.	O

The	O
methodology	O
is	O
applied	O
to	O
two	O
real	O
cases	O
of	O
combined	B:C3872815
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
with	O
6	O
and	O
12	O
months	O
of	O
treatment	O
.	O

The	O
methodology	O
is	O
applied	O
to	O
two	O
real	O
cases	O
of	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
with	O
6	O
and	O
12	O
months	O
of	O
treatment	B:C0087111
.	O

The	O
acoustica	O
l	O
evaluation	B:C0220825
indicates	O
that	O
pirfenidone	O
treatment	O
may	O
not	O
be	O
satisfactory	O
for	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
but	O
further	O
evaluation	O
has	O
to	O
be	O
performed	O
.	O

The	O
acoustica	O
l	O
evaluation	O
indicates	O
that	O
pirfenidone	B:C0298067
treatment	O
may	O
not	O
be	O
satisfactory	O
for	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
but	O
further	O
evaluation	O
has	O
to	O
be	O
performed	O
.	O

The	O
acoustica	O
l	O
evaluation	O
indicates	O
that	O
pirfenidone	O
treatment	B:C0087111
may	O
not	O
be	O
satisfactory	O
for	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
but	O
further	O
evaluation	O
has	O
to	O
be	O
performed	O
.	O

The	O
acoustica	O
l	O
evaluation	O
indicates	O
that	O
pirfenidone	O
treatment	O
may	O
not	O
be	O
satisfactory	O
for	O
combined	B:C3872815
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
but	O
further	O
evaluation	O
has	O
to	O
be	O
performed	O
.	O

The	O
acoustica	O
l	O
evaluation	O
indicates	O
that	O
pirfenidone	O
treatment	O
may	O
not	O
be	O
satisfactory	O
for	O
combined	O
pulmonary	I:C3872815
fibrosis	I:C3872815
emphysema	I:C3872815
syndrome	I:C3872815
patients	O
but	O
further	O
evaluation	B:C0220825
has	O
to	O
be	O
performed	O
.	O

